Hemolytic anemia is a diseased condition characterized by premature destruction of red blood cells (RBCs) and their removal from the blood circulatory system before their life span is over. Red blood cells also known as erythrocytes are disk like structures that carry oxygen from lungs to body organs and help in removing carbon dioxide from the body.
Usually red blood cells (RBCs) have a normal life span of 120 before they are removed from the blood stream by spleen. Red blood cells are produced by bone marrow. In people suffering from acquired (autoimmune) hemolytic anemia, bone marrows are unable to produce enough RBCs to meet body’s demand.
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/19732
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/19732
Treatment is based on three major aims, preventing the destruction of RBCs, increasing the RBCs count and treating the origin of illness. Blood transfusion, medications, plasmapheresis and surgeries are among major treatment options. Prednisone, rituximab, hydroxyurea and cyclosporine are some drugs that are usually prescribed for treating acquired (autoimmune) hemolytic anemia.
There are no exact incidence and prevalence statistics are available regarding the acquired (autoimmune) hemolytic anemia. According to sources from Elsevier, Inc. the incidence rate of all types of acquired (autoimmune) hemolytic anemias range from one new case per 100,000 general population to 300,000 per year.
The market will also be driven by unmet medical needs as there is no standard medicines available for treating acquired hemolytic anemia. Many companies are conducting clinical trials in order to introduce effective medicines for acquired hemolytic anemia.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/19732
Some major pharmaceutical companies and research institutions that are engaged in the development, manufacturing and marketing of drugs for this market include Novartis AG, Sanofi, Centre Hospitalier Universitaire Dijon, Institute of Hematology & Blood Diseases Hospital, Hoffmann-La Roche, National Cancer Institute (NCI), Agios Pharmaceuticals, Inc., Octapharma Pharmazeutika Produktionsges.m.b.H., National Heart, Lung, and Blood Institute (NHLBI) and Baxter Healthcare Corporation.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com